Abstract
Two small-molecule anticancer drugs have been approved by the US Food and Drug Administration. One of them is Eli Lilly and Company’s pirtobrutinib, a reversible kinase inhibitor intended for adults who have mantle cell lymphoma and have completed at least two lines of systemic therapy. The Menarini Group’s estrogen receptor agonist elacestrant is another oncology drug to receive a nod, for the treatment of ER+, HER2–, or ESR1-mutated breast cancer in postmenopausal women and adult men. The Italian company is currently awaiting approval for the compound from the European Medicines Agency.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
